Design Defect Claims Against Name Brand Zantac Defendants Preempted, MDL Judge Rules



DOCUMENTS
  • Order


WEST PALM BEACH, Fla. — A Florida federal judge has ruled that design defect claims filed against the makers of Zantac (ranitidine) are preempted by federal law because they seek to challenge the drugs’ Food and Drug Administration-approved formula.

However, in the Jan. 8 order, Judge Robin L. Rosenberg of the U.S. District Court for the Southern District of Florida granted plaintiffs leave to replead their design defect claims that are based upon the drugs’ labeling. The judge noted that certain states view the adequacy of drug labeling as part of a design defect claim, and the Changes Being Effected …






UPCOMING CONFERENCES




HarrisMartin's Mass Tort Settlements Conference - Sponsored by Milestone

June 27, 2024 - Buffalo, NY
The Richardson Hotel Buffalo

MORE DETAILS



HarrisMartin's MDL Conference: Video Game Addiction and the Latest Mass Tort Updates

May 29, 2024 - Salt Lake City, UT
The Grand America Hotel

MORE DETAILS